Introduction and Context
Obesity affects roughly 40% of U.S. adults and is a leading contributor to type 2 diabetes, cardiovascular disease, some cancers, and worse outcomes from infectious diseases. The condition is multifactorial — shaped by genetics, physiology, social and physical environments, food systems, and health care access. Recognizing the complexity and the rapid changes in treatment options and policy evidence, the American College of Physicians (ACP) issued a 2026 policy position paper titled “Public Policy Approaches to Addressing Adult Obesity” (Crowley et al., Ann Intern Med 2026). The statement emphasizes that addressing adult obesity requires coordinated action across the health care system, nutrition and agriculture policy, built environment planning, and research.
This article summarizes the ACP’s core recommendations, why the update was necessary, what changed or was emphasized compared with earlier guidance, and the practical implications for clinicians, health systems, and policymakers.
New Guideline Highlights
Major themes and policy directions in the 2026 ACP position paper:
– Universal payer coverage for a consistent, evidence-based package of obesity interventions that includes prevention and screening, intensive lifestyle treatment, pharmacologic therapies, and bariatric surgery. ACP explicitly calls on Medicare and Medicaid to cover evidence-based anti-obesity medications and opposes onerous restrictions that limit access.
– Financial and system-level strategies to lower price barriers for patients and payers, including support for policies that reduce drug costs and encourage insurer coverage consistency.
– Expansion of evidence-based “prescription food” programs and strengthened support for federal nutrition assistance (for example, sufficient SNAP funding and incentives for healthy food purchases).
– Development of a formal, evidence-based definition of ultraprocessed foods (UPFs) and policy actions to curb their contribution to poor diet quality and obesity risk, including support for sugar-sweetened beverage (SSB) taxes with revenue dedicated to diet-related disease prevention.
– Investment in physician education to improve obesity care, anti-bias training to reduce weight stigma in health care, and facility accommodations for people with larger bodies.
– Actions in community planning and transportation that promote safe active transportation and access to spaces for physical activity.
– A robust research agenda spanning etiology, UPF effects, screening and treatment best practices, and equity-focused implementation research.
Key takeaways for clinicians:
– Expect increasing policy momentum to expand coverage for medications and comprehensive treatment.
– Prepare teams to deliver physician-led, team-based models that may be better reimbursed under proposed policies.
– Anticipate greater attention to food-environment policies (taxes, SNAP changes, healthy food incentives) that will interact with clinical care.
Why This Update Was Issued
Several forces made a new ACP policy statement both timely and necessary:
– New therapeutic advances: The past five years saw the emergence of more effective pharmacologic agents for chronic weight management (for example, greater weight loss with GLP-1 receptor agonists such as semaglutide), prompting reconsideration of treatment access, long-term management, and payer coverage (Wilding et al., NEJM 2021).
– Persistent access barriers: High out-of-pocket costs, inconsistent payer coverage, prior authorization burdens, and age or BMI cutoffs limit patient access to pharmacotherapy and bariatric surgery.
– Growing policy evidence on food environment interventions: Evidence linking ultraprocessed foods to weight gain and trials showing the impact of fiscal measures (for example, taxes on sugar-sweetened beverages) support public policy levers to change population diets (Hall et al., Cell Metab 2019; WHO report on fiscal policies 2016).
– Recognition of stigma and bias: Weight stigma in society and health care settings worsens outcomes and reduces care-seeking; the ACP grounds its recommendations in a need to reduce stigma and use person-first language.
Updated Recommendations and Key Changes (Compared with Prior ACP Guidance)
The 2026 paper advances several policy positions that are newer or more strongly worded than many earlier statements from professional societies:
– Explicit call for payer coverage of anti-obesity medications: Whereas past guidance emphasized behavioral treatment and surgery, the 2026 ACP statement specifically urges Medicare and Medicaid to cover evidence-based medications and opposes onerous restrictions (e.g., arbitrary BMI cutoffs, mandatory step therapy without clinical justification).
– Greater emphasis on ultraprocessed foods and formal definitions: ACP urges development of an evidence-based definition for UPFs and supports targeted policy responses — a more specific stance than many previous guidelines that focused primarily on nutrient-based guidance.
– Stronger linkage of SSB and unhealthy-food taxes to funding obesity prevention and treatment programs, including directing revenue to evidence-based interventions.
– Calls for clinician training in obesity care and nutrition to be explicitly integrated into medical education curricula, with recommended reimbursement to support physician-led team-based models.
Table: Selected 2026 ACP recommendations (excerpt)
– Recommendation 1: All payers should cover a consistent, comprehensive package of evidence-based obesity interventions (screening, intensive lifestyle treatment, pharmacologic treatments, weight loss surgery). (ACP strong policy recommendation)
– Recommendation 1a: Medicare and Medicaid should cover evidence-based medications to manage obesity.
– Recommendation 1b: Oppose onerous restrictions on obesity treatment (strong policy stance).
– Recommendation 2: Expand access to nutritious foods through evidence-based prescription food programs.
– Recommendation 7: Develop formal definition of ultraprocessed foods and consider appropriate restrictions; raise excise taxes on sugar-sweetened beverages; test taxes on unhealthy calorie-dense, low-nutrient foods; dedicate revenues to diet-related prevention/treatment.
Topic-by-Topic Recommendations
Screening and Diagnosis
– ACP reiterates that obesity is a chronic disease that merits systematic screening in adults. Screening in clinical settings should include measurement of height, weight, and BMI calculation and, where appropriate, waist circumference and assessment of obesity-related complications.
– Clinicians should move beyond BMI alone to assess comorbid conditions (type 2 diabetes, dyslipidemia, hypertension) and functional impact, and use shared decision-making to plan interventions.
Treatment Pathways and Coverage
– Core package: ACP recommends coverage of (1) prevention and screening services; (2) intensive lifestyle interventions (behavioral therapy, structured programs); (3) pharmacologic therapies with demonstrated efficacy; and (4) bariatric surgery when clinically indicated.
– Pharmacotherapies: Given recent trial evidence showing clinically meaningful weight loss with GLP-1 receptor agonists (e.g., semaglutide) and related agents (Wilding et al., NEJM 2021), ACP calls for coverage of evidence-based medications and opposes restrictive policies that obstruct access.
– Surgical care: Support for coverage of bariatric surgery for appropriate candidates, including coverage equity for older and publicly insured adults who meet criteria.
Reimbursement and Care Models
– ACP supports sufficient reimbursement for physician-led, multidisciplinary team-based care, recognizing that effective obesity management often requires dietitians, mental health professionals, exercise specialists, and care coordination.
Food Systems and Nutrition Policy
– Nutrition assistance: Support for adequate funding for SNAP and similar programs, and for SNAP policy changes that increase healthy food access (for example, incentives for fruits and vegetables).
– Prescription food programs: Support pilots and scale-up of programs that allow clinicians to prescribe or refer patients to nutritious foods affordable and available in their communities.
– UPFs and fiscal policy: ACP calls for an evidence-based definition of UPFs, supports excise taxes on sugar-sweetened beverages, and suggests testing taxes on unhealthy, calorie-dense, low-nutrient foods, with tax revenues deployed to prevention and treatment programs.
Built Environment and Transportation
– ACP recommends community planning that encourages safe active transportation (walking, biking), and policies that create accessible, low-emission environments that make physical activity safe and feasible for people of all abilities.
Stigma and Education
– ACP supports strategies to reduce weight bias and stigma across health care settings, encourages person-first language (“person with obesity”), calls for accommodations in clinical settings (appropriate equipment, seating, gowns), and recommends formal obesity and nutrition curricula in medical education.
Research Priorities
– The ACP enumerates a research agenda including: causal drivers of obesity in adults; randomized and implementation trials on UPFs; best practices for screening, prevention, and long-term treatment; and research focused on achieving equitable care for historically marginalized groups.
Expert Commentary and Insights
Committee rationale and consensus
– The ACP Health and Public Policy Committee framed obesity as a chronic medical condition influenced by broader social determinants and systems-level drivers. The committee emphasized that clinical treatment alone cannot reverse population-level trends; policy solutions that reshape food environments, expand access to effective treatments, and remove financial barriers are essential.
Key controversies and areas of debate
– Medication access vs. long-term evidence: Experts widely acknowledge the substantial short-term benefits of newer pharmacotherapies (e.g., GLP-1 agonists). However, questions remain about long-term safety, optimal duration of therapy, relapse after discontinuation, and how best to integrate medications with behavioral and surgical options.
– UPFs classification and regulation: While there is growing evidence linking ultraprocessed food consumption to increased calorie intake and weight gain (Hall et al., Cell Metab 2019; Monteiro et al., Public Health Nutr 2019), the committee recognized the challenge of defining UPFs rigorously and avoiding unintended consequences (e.g., restricting access for low-income populations without supportive alternatives).
– Taxes and SNAP eligibility changes: The committee supports SSB taxes with revenue directed to prevention and treatment but cautions that changes to SNAP food eligibility must avoid stigmatizing beneficiaries and must not reduce caloric access without providing healthy alternatives.
Voices from clinical practice
– The committee emphasized that clinicians often lack the training, time, and reimbursement to provide comprehensive obesity care; policy levers to reimburse team-based models and integrate nutrition counseling into routine practice would have immediate clinical impact.
Practical Implications for Clinicians, Health Systems, and Policymakers
For clinicians and practices:
– Prepare for expanded pharmacotherapy access: Review evidence and develop protocols for selecting candidates, monitoring effectiveness, and managing side effects. Anticipate payer prior-authorization challenges in the near term and advocate for evidence-based coverage.
– Build team-based care pathways: Invest in allied health professionals (registered dietitians, behavioral health, exercise physiologists) and document outcomes to support reimbursement.
– Reduce stigma: Implement training on weight bias, adopt person-first language, and ensure facility accommodations (scales, chairs, gowns) are inclusive.
For health systems and payers:
– Consider covering a standardized package of interventions that align with ACP recommendations; pilot value-based contracts for obesity care tied to meaningful outcomes.
– Support prescription food programs and community partnerships that increase access to healthy foods, especially in food-insecure areas.
For policymakers:
– Work to align Medicaid and Medicare coverage policies with current evidence, including coverage of evidence-based medications and surgical interventions when clinically indicated.
– Design fiscal policies (e.g., SSB taxes) with equity in mind and direct revenues to community prevention and treatment programs.
Patient vignette (illustrative):
Maria is a 48-year-old woman with BMI 34 kg/m2, hypertension, and insulin resistance. She has tried structured lifestyle programs with modest success but continues to struggle with weight-related symptoms and glycemic control. Her clinician discusses options including an intensive lifestyle program, consideration of GLP-1–based pharmacotherapy, and a referral to a dietitian. Previously her insurer denied coverage for anti-obesity medication citing a rigid BMI cutoff and required step therapy. Under ACP’s policy recommendations — if implemented — Maria’s insurer would cover evidence-based medication when clinically appropriate, support team-based care, and potentially enroll her in a prescription-food program to address food access barriers. Tackling structural barriers and providing comprehensive care could improve Maria’s outcomes and reduce long-term complications.
Research and Implementation Needs
ACP highlights these priority research domains:
– Long-term comparative effectiveness of medications, behavioral programs, and surgery, including durability and relapse rates.
– Rigorous trials to define and quantify the health effects of ultraprocessed foods and to evaluate feasible policy interventions.
– Implementation science on scaling team-based care in diverse health care settings and financing models that ensure equitable access.
– Social and behavioral research on interventions to reduce weight stigma and improve clinician–patient communication.
Conclusion
The 2026 ACP position paper reframes obesity as a condition that demands coordinated clinical, policy, and societal responses. Its central message: clinical treatments — from lifestyle programs to the latest pharmacotherapies and surgery — must be available and affordable, and structural actions on food systems, taxation, built environments, and education are necessary complements. For clinicians and health systems, the paper signals a likely policy shift toward broader payer coverage and stronger support for team-based care. For policymakers, it offers concrete priorities: fund nutrition assistance and prescription food programs, develop a science-based approach to ultraprocessed foods, and use fiscal policies wisely to finance prevention and treatment programs while safeguarding equity.
References
1. Crowley R, Beachy M, Carr P; Health and Public Policy Committee of the American College of Physicians. Public Policy Approaches to Addressing Adult Obesity: A Position Paper From the American College of Physicians. Ann Intern Med. 2026 Aug 4. doi: 10.7326/ANNALS-26-00864.
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
3. Hall KD, Ayuketah A, Brychta R, et al. Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake. Cell Metab. 2019;30(1):67-77.e3. doi:10.1016/j.cmet.2019.05.008
4. Monteiro CA, Cannon G, Lawrence M, et al. Ultra-processed foods, diet quality, and health using the NOVA classification system. Public Health Nutr. 2019;22(11):1729-1739. doi:10.1017/S1368980019000647
5. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. J Am Coll Cardiol. 2014;63(25 Pt B):2985-3023. doi:10.1016/j.jacc.2013.11.004
6. Centers for Disease Control and Prevention. Adult Obesity Prevalence Maps. CDC website. https://www.cdc.gov/obesity/data/prevalence-maps.html. Accessed July 2026.
7. World Health Organization. Fiscal policies for diet and the prevention of noncommunicable diseases: technical meeting report, 2015. Geneva: WHO; 2016. https://www.who.int/publications/i/item/9789241511247
8. Puhl RM, Heuer CA. The stigma of obesity: a review and update. Obesity (Silver Spring). 2009;17(5):941-964. doi:10.1038/oby.2008.636
(For clinicians and systems implementing the ACP recommendations, consult the full ACP position paper for complete language and context.)
